Telix Completes Phase 3 BiPASS Study Enrollment, Aligns with FDA on NDA Pathway — Telix Pharmaceuticals Limited

Event summary

Telix completed enrollment of 350 patients in the Phase 3 BiPASS study for prostate cancer imaging in the pre-biopsy setting.
The study evaluates the diagnostic performance of 68Ga-PSMA-PET combined with MRI for detecting prostate cancer prior to biopsy.
Telix aligned with the FDA on a New Drug Application (NDA) pathway that, if approved, would support reimbursement and broaden patient access.
BiPASS builds on the PRIMARY and PRIMARY2 studies, which demonstrated significant improvements in diagnostic accuracy and reduction of unnecessary biopsies.

The big picture

Telix's completion of the BiPASS study enrollment and alignment with the FDA on the NDA pathway could transform the diagnostic landscape for prostate cancer. The study's success would establish precision imaging as a critical step in initial diagnosis, potentially reducing the need for invasive biopsies and improving patient outcomes. This aligns with broader industry trends toward non-invasive diagnostic methods and personalized treatment approaches in oncology.

What we're watching

Regulatory Approval: Whether the FDA will approve the NDA pathway for BiPASS, which could significantly expand the market for 68Ga-PSMA-PET imaging.
Market Expansion: The pace at which Telix can broaden access to 68Ga-PSMA-PET imaging across a larger patient population if BiPASS meets its primary objectives.
Clinical Impact: How the combination of MRI and PSMA-PET/CT with Telix's proprietary agents will affect diagnostic accuracy and reduce unnecessary biopsies.